Spice drugs: cannabinoids as a new designer drugs

被引:38
作者
Mustata, Cristina [1 ,2 ]
Torrens, Marta [1 ,3 ]
Pardo, Ricardo [1 ,2 ]
Perez, Clara [1 ,2 ]
Farre, Magi [1 ,2 ]
机构
[1] Hosp del Mar, IMIM, Unidad Farmacol Humana & Neurociencias, Programa Neuropsicofarmacol, Barcelona 08003, Spain
[2] Univ Autonoma Barcelona, Barcelona, Spain
[3] Hosp del Mar, IMIM, Unidad Toxicomanias, Inst Atencio Psiquiatr Salut Mental & Toxicomanie, Barcelona 08003, Spain
关键词
Spice drugs; synthetic cannabinoids designer drugs; JWH-018; CP; 47497; JWH-073; HU-210; RECEPTORS; CB1; CLASSIFICATION; PHARMACOLOGY; ANANDAMIDE; AGONISTS;
D O I
10.20882/adicciones.227
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
Some smokable herbal mixtures under the brand name Spice drugs have been sold on the Internet and in specialised shops (smart shops) since 2004. The mixtures are advertised as an exotic incense blend which releases a rich aroma and not for human consumption. When smoked, Spice drugs products have been reported by some users to have effects similar to those of cannabis. Spice drugs have received intensive attention in drug forums due to the possibility to obtain a non legal substitute of cannabis. Forensic analyses have found different potent synthetic cannabinoid agonists in some Spice drugs products, as JWH-018, CP 47497, JWH-073 and HU-210. There are few data about its pharmacological properties in animals, but nothing about its toxicity. At present, almost nothing is known about the pharmacology, toxicology and safety profile of such compounds in humans, except the opinions of consumers in internet forums. Neither the herbal ingredients of Spice drugs, nor any of the synthetic cannabinoids found in them, are internationally controlled under the 1961 or 1971 UN drug control conventions. Some European countries have recently taken legal actions to ban or otherwise control Spice drugs products and related compounds. These cannabinoid substances can be considered as new products to be added to the list of "designer drugs".
引用
收藏
页码:181 / 186
页数:6
相关论文
共 50 条
[1]   Synthetic cannabinoids: the hidden side of Spice drugs [J].
Pintori, Nicholas ;
Loi, Barbara ;
Mereu, Maddalena .
BEHAVIOURAL PHARMACOLOGY, 2017, 28 (06) :409-419
[2]   New Designer Drugs (Synthetic Cannabinoids and Synthetic Cathinones): Review of Literature [J].
Cottencin, Olivier ;
Rolland, Benjamin ;
Karila, Laurent .
CURRENT PHARMACEUTICAL DESIGN, 2014, 20 (25) :4106-4111
[3]   New Designer Drugs [J].
Levine, Michael ;
Lovecchio, Frank .
EMERGENCY MEDICINE CLINICS OF NORTH AMERICA, 2021, 39 (03) :677-687
[4]   Spice drugs as a new trend: Mode of action, identification and legislation [J].
Vardakou, I. ;
Pistos, C. ;
Spiliopoulou, Ch. .
TOXICOLOGY LETTERS, 2010, 197 (03) :157-162
[5]   Spice drugs are more than harmless herbal blends: A review of the pharmacology and toxicology of synthetic cannabinoids [J].
Seely, Kathryn A. ;
Lapoint, Jeff ;
Moran, Jeffery H. ;
Fattore, Liana .
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2012, 39 (02) :234-243
[6]   Beyond THC: the new generation of cannabinoid designer drugs [J].
Fattore, Liana ;
Fratta, Walter .
FRONTIERS IN BEHAVIORAL NEUROSCIENCE, 2011, 5
[7]   Detection and Quantification of New Designer Drugs in Human Blood: Part 2 Designer Cathinones [J].
Ammann, Dominic ;
McLaren, Jenna M. ;
Gerostamoulos, Dimitri ;
Beyer, Jochen .
JOURNAL OF ANALYTICAL TOXICOLOGY, 2012, 36 (06) :381-389
[8]   FAPA mass spectrometry of designer drugs [J].
Smoluch, Marek ;
Gierczyk, Blazej ;
Reszke, Edward ;
Babij, Michal ;
Gotszalk, Teodor ;
Schroeder, Grzegorz ;
Silberring, Jerzy .
TALANTA, 2016, 146 :29-33
[9]   Designer drugs: a medicinal chemistry perspective [J].
Carroll, F. Ivy ;
Lewin, Anita H. ;
Mascarella, S. Wayne ;
Seltzman, Herbert H. ;
Reddy, P. Anantha .
ADDICTION REVIEWS, 2012, 1248 :18-38
[10]   Characterization of in vitro Metabolites of Methylenedioxy Designer Drugs [J].
Yu, Jun Sang ;
Jo, So Young ;
Park, Il-Ho ;
Yoo, Hye Hyun .
MASS SPECTROMETRY LETTERS, 2023, 14 (01) :1-8